Recently, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors have been shown to reduce LDL cholesterol levels and ASCVD risk across multiple patient cohorts. Here, PCSK9 is linked to atherosclerosis.